The following is the initial article about the rights offering back in 2011 for LXRX:
"Lexicon Pharmaceuticals, Inc. announced that it has commenced its previously announced rights offering pursuant to an effective registration statement and began mailing a prospectus and other rights offering materials to its stockholders. In the rights offering, stockholders will receive one non-transferable subscription right for every share of common stock owned as of November 21, 2011 , which was the record date for the rights offering. Each subscription right will entitle stockholders to purchase 0.427175 shares of common stock at a subscription price of $1.13 per share. For example, a stockholder who owns 1,000 shares of common stock on the record date will be granted 1,000 subscription rights entitling the stockholder to purchase 427 shares of common stock (427.175 rounded down to the nearest whole share number) for an aggregate purchase price of $482.51 . Stockholders who exercise their basic subscription privilege in full may also exercise an over-subscription privilege to purchase additional shares that remain unsubscribed at the expiration of the rights offering, subject to availability and proration. Lexicon is offering an aggregate of 144,247,542 shares of common stock in the rights offering and, if fully subscribed, aggregate gross proceeds to Lexicon will be approximately $163 million. The subscription rights will be exercisable until December 22, 2011 ."
On November 21st, 2011 the price of LXRX was $.98 - 1.04. The offering was $1.13. During the rights offering period the stock price went steadily up to a high of $1.27 on December 9th, 2011. Then the stock plummeted to a low of .94 and then it went back up to $1.06-1.18 on the close of the rights offering and then the stock steadily climbed through the following year reaching a high of $3.28 on July 17th, 2012., further the stock has stayed above $1.56 reaching $3.18 on Oct. 1st 2013. LXRX looses money.